Biota says swine flu pandemic speculation overdone as share...

Biota says swine flu pandemic speculation overdone as share price soars
By George Lekakis
Herald Sun
April 28, 2009 12:00am

Swine flu fears boost drug giants
Drugmakers are set to benefit from fears of a global pandemic triggered by a new flu strain which...
Views today: 0Sorry, this video is no longer available.Biota warns against pandemic speculation
Shares skyrocket on swine flu
Biota share price: Check the latest
Twitter: Follow our business blog
BIOTA boss Peter Cook yesterday warned investors against speculating in the company's scrip on the back of reports that the so-called "swine flu" could trigger a lethal pandemic.

Shares in the Melbourne-based flu drug developer yesterday soared almost 82 per cent or 71 cents to close at $1.58.

More than 17 million shares were traded, making it the busiest trading day since November 2005 when the company's scrip was talked up amid fears stemming from the avian flu outbreak.

After passing through $2 in 2005 Biota's stock price rapidly retraced as it became apparent that the bird flu threat to human health was not as universal as some had feared.

Markets across Asia were affected yesterday, with airline and tourism stocks hit hard on fears of a more widespread flu outbreak.

While Mr Cook acknowledged that a new strain of swine flu was a cause for concern, he noted that recent cases in the United States and Britain had been associated with relatively mild symptoms.

Related Coverage
Pandemic alert raised as flu spreads
The Australian, 28 Apr 2009
Wall St falls as swine flu spreads
Herald Sun, 28 Apr 2009
'Not enough flu drugs in stockpile'
NEWS.com.au, 28 Apr 2009
Swine flu limits gains
The Australian, 28 Apr 2009
Swine flu can't be stopped
Courier Mail, 28 Apr 2009 "When we went through the avian influenza event four years ago, every time there was a report of a goose or duck dying in Europe our stock price went up," he said.

"If people speculate in the stock on those terms then they will end up disappointed.

"To assert, right now, that this (swine flu) will cause a massive rise in sales, well, that class of response is erroneous and lacks understanding."

Biota licenses the rights for its flu drug Relenza to US pharmaceuticals giant GlaxoSmithKline and collects a royalty for every course sold.

Biota collects 7 cents in every $1 generated by Glaxo through Relenza sales.

Australian broking analysts last week upgraded their earnings forecasts for Biota after Glaxo announced big increases in Relenza sales in Britain and Japan.

The governments of both countries are re-stocking their flu drug stockpiles after they ran down during the northern hemisphere winter.

Mr Cook said it was difficult to assess the long-term impact of swine flu on Relenza's sales, but it would probably be positive.

"This outbreak has probably concentrated the minds of US administrators on working out whether they are prepared for a real pandemic," he said.

"An important part of being prepared is to ensure that a nation's drug inventory is adequate to meet a crisis," Mr Cook said.

Mr Storey cautioned against expectations that the swine virus would trigger a pandemic but said any restocking by governments would support the company's share price.

Before yesterday's rally, Mr Storey had set a 12-month price target of $1.38 on Biota.